# Angi Inc.: financial statements, quarterly

ANGI · Nasdaq · CIK 1705110 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/angi.md) · [Financials](/companies/angi/financials.md) · [Filings](/companies/angi/filings.md) · [Insiders](/companies/angi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/angi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [351](/filings/0001705110-24-000114.md) | [300 d](/filings/0001705110-26-000011.md) | [305](/filings/0001705110-25-000044.md) | [315](/filings/0001705110-25-000099.md) | [297](/filings/0001705110-25-000134.md) | [268 d](/filings/0001705110-26-000011.md) | [246](/filings/0001705110-26-000044.md) | [278](/filings/0001705110-26-000078.md) | [266](/filings/0001705110-25-000134.md) | [241 d](/filings/0001705110-26-000011.md) | [238](/filings/0001705110-26-000044.md) | [248](/filings/0001705110-26-000078.md) |
| Cost of revenue | $m | [13.7](/filings/0001705110-24-000114.md) | [17.2 d](/filings/0001705110-26-000011.md) | [12.5](/filings/0001705110-25-000044.md) | [14.2](/filings/0001705110-25-000099.md) | [14.8](/filings/0001705110-25-000134.md) | [16.2 d](/filings/0001705110-26-000011.md) | [13.0](/filings/0001705110-26-000044.md) | [13.1](/filings/0001705110-26-000078.md) | [12.5](/filings/0001705110-25-000134.md) | [8.8 d](/filings/0001705110-26-000011.md) | [9.7](/filings/0001705110-26-000044.md) | [11.7](/filings/0001705110-26-000078.md) |
| Gross profit | $m | [338](/filings/0001705110-24-000114.md) | [283 d](/filings/0001705110-26-000011.md) | [293](/filings/0001705110-25-000044.md) | [301](/filings/0001705110-25-000099.md) | [282](/filings/0001705110-25-000134.md) | [252 d](/filings/0001705110-26-000011.md) | [233](/filings/0001705110-26-000044.md) | [265](/filings/0001705110-26-000078.md) | [253](/filings/0001705110-25-000134.md) | [232 d](/filings/0001705110-26-000011.md) | [228](/filings/0001705110-26-000044.md) | [236](/filings/0001705110-26-000078.md) |
| Research and development | $m | [21.5](/filings/0001705110-24-000114.md) | [24.2 d](/filings/0001705110-26-000011.md) | [23.8](/filings/0001705110-25-000044.md) | [24.8](/filings/0001705110-25-000099.md) | [24.3](/filings/0001705110-25-000134.md) | [22.5 d](/filings/0001705110-26-000011.md) | [27.1](/filings/0001705110-26-000044.md) | [23.6](/filings/0001705110-26-000078.md) | [20.7](/filings/0001705110-25-000134.md) | [15.9 d](/filings/0001705110-26-000011.md) | [10.4](/filings/0001705110-26-000044.md) | [10.9](/filings/0001705110-26-000078.md) |
| Operating income | $m | [(7.9)](/filings/0001705110-24-000114.md) | [7.6 d](/filings/0001705110-26-000011.md) | [2.7](/filings/0001705110-25-000044.md) | [9.2](/filings/0001705110-25-000099.md) | [7.8](/filings/0001705110-25-000134.md) | [2.2 d](/filings/0001705110-26-000011.md) | [20.0](/filings/0001705110-26-000044.md) | [17.7](/filings/0001705110-26-000078.md) | [21.8](/filings/0001705110-25-000134.md) | [5.9 d](/filings/0001705110-26-000011.md) | [(9.5)](/filings/0001705110-26-000044.md) | [(234)](/filings/0001705110-26-000078.md) |
| Interest expense | $m | [5.0](/filings/0001705110-23-000088.md) | [5.0 d](/filings/0001705110-24-000012.md) | [5.0](/filings/0001705110-24-000038.md) | [5.0](/filings/0001705110-25-000099.md) | [5.0](/filings/0001705110-25-000134.md) | [5.0 d](/filings/0001705110-26-000011.md) | [5.0](/filings/0001705110-26-000044.md) | [5.1](/filings/0001705110-26-000078.md) | [5.1](/filings/0001705110-25-000134.md) | [5.3 d](/filings/0001705110-26-000011.md) | [5.3](/filings/0001705110-26-000044.md) | [4.8](/filings/0001705110-26-000078.md) |
| Income tax | $m | [(6.1)](/filings/0001705110-24-000114.md) | [5.7 d](/filings/0001705110-26-000011.md) | [3.5](/filings/0001705110-25-000044.md) | [4.6](/filings/0001705110-25-000099.md) | [(26.6)](/filings/0001705110-25-000134.md) | [1.7 d](/filings/0001705110-26-000011.md) | [4.7](/filings/0001705110-26-000044.md) | [6.5](/filings/0001705110-26-000078.md) | [10.2](/filings/0001705110-25-000134.md) | [(2.7) d](/filings/0001705110-26-000011.md) | [(0.7)](/filings/0001705110-26-000044.md) | [(0.9)](/filings/0001705110-26-000078.md) |
| Net income | $m | [(5.3)](/filings/0001705110-24-000114.md) | [(5.5) d](/filings/0001705110-26-000011.md) | [(1.3)](/filings/0001705110-25-000044.md) | [4.1](/filings/0001705110-25-000099.md) | [35.4](/filings/0001705110-25-000134.md) | [(1.3) d](/filings/0001705110-26-000011.md) | [15.1](/filings/0001705110-26-000044.md) | [10.9](/filings/0001705110-26-000078.md) | [10.6](/filings/0001705110-25-000134.md) | [7.2 d](/filings/0001705110-26-000011.md) | [(9.0)](/filings/0001705110-26-000044.md) | [(231)](/filings/0001705110-26-000078.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001705110-24-000114.md) | not reported | [(0.03)](/filings/0001705110-25-000044.md) | [0.07](/filings/0001705110-25-000099.md) | [0.70](/filings/0001705110-25-000134.md) | not reported | [0.30](/filings/0001705110-26-000044.md) | [0.23](/filings/0001705110-26-000078.md) | [0.23](/filings/0001705110-25-000134.md) | not reported | [(0.22)](/filings/0001705110-26-000044.md) | [(5.70)](/filings/0001705110-26-000078.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0001705110-24-000114.md) | not reported | [(0.03)](/filings/0001705110-25-000044.md) | [0.07](/filings/0001705110-25-000099.md) | [0.71](/filings/0001705110-25-000134.md) | not reported | [0.30](/filings/0001705110-26-000044.md) | [0.23](/filings/0001705110-26-000078.md) | [0.24](/filings/0001705110-25-000134.md) | not reported | [(0.22)](/filings/0001705110-26-000044.md) | [(5.70)](/filings/0001705110-26-000078.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [367](/filings/0001705110-24-000114.md) | [364](/filings/0001705110-26-000011.md) | [363](/filings/0001705110-25-000044.md) | [385](/filings/0001705110-25-000099.md) | [395](/filings/0001705110-25-000134.md) | [416](/filings/0001705110-26-000078.md) | [387](/filings/0001705110-26-000044.md) | [362](/filings/0001705110-26-000078.md) | [341](/filings/0001705110-25-000134.md) | [304](/filings/0001705110-26-000078.md) | [245](/filings/0001705110-26-000044.md) | [189](/filings/0001705110-26-000078.md) |
| Current assets | $m | [516](/filings/0001705110-23-000088.md) | [487](/filings/0001705110-25-000018.md) | [482](/filings/0001705110-24-000038.md) | [516](/filings/0001705110-24-000078.md) | [500](/filings/0001705110-24-000114.md) | [495](/filings/0001705110-26-000011.md) | [465](/filings/0001705110-25-000044.md) | [443](/filings/0001705110-25-000099.md) | [407](/filings/0001705110-25-000134.md) | [366](/filings/0001705110-26-000078.md) | [313](/filings/0001705110-26-000044.md) | [256](/filings/0001705110-26-000078.md) |
| Total assets | $m | [1,906](/filings/0001705110-23-000088.md) | [1,856](/filings/0001705110-25-000018.md) | [1,835](/filings/0001705110-24-000038.md) | [1,852](/filings/0001705110-24-000078.md) | [1,856](/filings/0001705110-24-000114.md) | [1,831](/filings/0001705110-26-000011.md) | [1,806](/filings/0001705110-25-000044.md) | [1,789](/filings/0001705110-25-000099.md) | [1,747](/filings/0001705110-25-000134.md) | [1,680](/filings/0001705110-26-000078.md) | [1,625](/filings/0001705110-26-000044.md) | [1,325](/filings/0001705110-26-000078.md) |
| Current liabilities | $m | [304](/filings/0001705110-23-000088.md) | [259](/filings/0001705110-25-000018.md) | [242](/filings/0001705110-24-000038.md) | [261](/filings/0001705110-24-000078.md) | [244](/filings/0001705110-24-000114.md) | [232](/filings/0001705110-26-000011.md) | [216](/filings/0001705110-25-000044.md) | [248](/filings/0001705110-25-000099.md) | [215](/filings/0001705110-25-000134.md) | [222](/filings/0001705110-26-000078.md) | [209](/filings/0001705110-26-000044.md) | [214](/filings/0001705110-26-000078.md) |
| Long-term debt | $m | [496](/filings/0001705110-23-000088.md) | [496](/filings/0001705110-25-000018.md) | [496](/filings/0001705110-24-000038.md) | [496](/filings/0001705110-24-000078.md) | [497](/filings/0001705110-24-000114.md) | [497](/filings/0001705110-26-000011.md) | [497](/filings/0001705110-25-000044.md) | [497](/filings/0001705110-25-000099.md) | [497](/filings/0001705110-25-000134.md) | [498](/filings/0001705110-26-000078.md) | [471](/filings/0001705110-26-000044.md) | [398](/filings/0001705110-26-000078.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,042](/filings/0001705110-23-000088.md) | [1,041](/filings/0001705110-25-000018.md) | [1,039](/filings/0001705110-24-000038.md) | [1,040](/filings/0001705110-24-000078.md) | [1,070](/filings/0001705110-24-000114.md) | [1,063](/filings/0001705110-26-000078.md) | [1,049](/filings/0001705110-26-000078.md) | [1,002](/filings/0001705110-26-000078.md) | [994](/filings/0001705110-25-000134.md) | [927](/filings/0001705110-26-000078.md) | [915](/filings/0001705110-26-000078.md) | [688](/filings/0001705110-26-000078.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [11.0 d](/filings/0001705110-23-000088.md) | [5.4 d](/filings/0001705110-26-000011.md) | [22.3](/filings/0001705110-25-000044.md) | [62.7 d](/filings/0001705110-25-000099.md) | [30.9 d](/filings/0001705110-25-000134.md) | [40.0 d](/filings/0001705110-26-000011.md) | [(3.1)](/filings/0001705110-26-000044.md) | [57.1 d](/filings/0001705110-26-000078.md) | [21.0 d](/filings/0001705110-25-000134.md) | [30.1 d](/filings/0001705110-26-000011.md) | [(17.9)](/filings/0001705110-26-000044.md) | [27.2 d](/filings/0001705110-26-000078.md) |
| Capital expenditure | $m | [13.8 d](/filings/0001705110-24-000114.md) | [11.7 d](/filings/0001705110-26-000011.md) | [12.8](/filings/0001705110-25-000044.md) | [12.6 d](/filings/0001705110-25-000099.md) | [12.1 d](/filings/0001705110-25-000134.md) | [12.9 d](/filings/0001705110-26-000011.md) | [12.6](/filings/0001705110-26-000044.md) | [12.3 d](/filings/0001705110-26-000078.md) | [16.0 d](/filings/0001705110-25-000134.md) | [18.7 d](/filings/0001705110-26-000011.md) | [15.7](/filings/0001705110-26-000044.md) | [15.0 d](/filings/0001705110-26-000078.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [503](/filings/0001705110-23-000088.md) | [505](/filings/0001705110-24-000038.md) | [506](/filings/0001705110-24-000078.md) | [506](/filings/0001705110-24-000114.md) | [50.3](/filings/0001705110-25-000044.md) | [50.7](/filings/0001705110-25-000099.md) | [50.5](/filings/0001705110-25-000134.md) | [50.5](/filings/0001705110-26-000044.md) | [47.7](/filings/0001705110-26-000078.md) | [45.1](/filings/0001705110-25-000134.md) | [40.2](/filings/0001705110-26-000044.md) | [40.5](/filings/0001705110-26-000078.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.